ALTERNATIVE APPROACHES TO THE TREATMENT OF INSULIN RESISTANCE
Keywords:insulin resistance, treatment, prevention
According to modern notions, insulin resistance (IR) is defined as a violation of the biological response to insulin stimulation of target tissues. Despite the possible occurrence of IR as a physiological reaction, IP is often associated with metabolic disorders and pathological states, including hypothyroidism, Cushing's disease / syndrome, polycystic ovary syndrome, acromegaly, nonalcoholic fatty liver disease, chronic kidney disease, dementia, as well as malignant neoplasms of the breast, lungs, prostate and colon. Сonvincing evidence of the adverse effects of reduced insulin sensitivity on the course of COVID-19 has been obtained given today's realities. At the same time, among the wide range of pathological conditions associated with IR, decreased insulin sensitivity is associated mainly with metabolic syndrome, cardiovascular disease and type 2 diabetes. Taking into account the multifactorial effects of IR and its role in the development and progression of a number of diseases, the need for active preventive measures and targeted treatment of patients with IR markers is currently justified. First of all, normalization of the patient's body weight is defined as treatment-and-prophylactic measures, because IR is usually combined with visceral type of obesity. As non-drug methods of normalization of body weight in modern recommendations two main approaches are specified: a dietary mode and adequate to a state of the patient's health dosed physical activities. When combining IR and diabetes, antihyperglycemic drugs are prescribed, which increase the sensitivity of peripheral tissues to insulin, or so-called sensitizers. Recently, the possibility of using dietary supplements in the prevention and treatment of many diseases, including IR, both in its isolated development and in the structure of comorbid pathology is being considered. In this regard, you should pay attention to the product of EXPERT PHARMA - GlucoCare ™. This remedy contains a unique combination of active substances, which determines the versatility of its effects, in particular in the treatment of patients with IR.
Freeman AM, Pennings N. Insulin Resistance. In: StatPearls, 2021, available at: https://www.ncbi.nlm.nih.gov/books/NBK507839/.
Castro AV, Kolka CM, Kim SP, Bergman RN. Arq Bras Endocrinol Metabol 2014;58(6): 600-609. https://doi.org/10.1590/0004-2730000003223.
Skybchyk VA. Ukr Med Chasopys 2006;6(56): 61-68.
Johnson AM, Olefsky JM. Cell 2013;152(4): 673-684. https://doi.org/10.1016/j.cell.2013.01.041.
Govers E. Healthcare 2015;3(2): 408-416. https://doi.org/10.3390/healthcare3020408.
Tjuzikov I. Saharnyj Diabet 2014;17(1): 47-56. https://doi.org/10.14341/DM2014147-56.
Dev R, Bruera E, Dalal S. Ann Oncol 2018;29(2): ii18-ii26. https://doi.org/10.1093/annonc/mdx815.
Ferreira LSS, Fernandes CS, Vieira MNN, De Felice FG. Front Neurosci 2018;12: 830. https://doi.org/10.3389/fnins.2018.00830.
Machado FVC, Pitta F, Hernandes NA, Bertolini GL. Endocrine 2018;61(1): 17-22. https://doi.org/10.1007/s12020-018-1554-z.
Finucane FM, Davenport C. Front Public Health 2020;8: 184. https://doi.org/10.3389/fpubh.2020.00184.
Pan'kiv VI. Praktychna Angiologija 2012;5-6: 54-55.
Ormazabal V, Nair S, Elfeky O, et al. Cardiovasc Diabetol 2018;17: 122. https://doi.org/10.1186/s12933-018-0762-4.
Nolan CJ, Prentki M. Diab Vasc Dis Res 2019;16(2): 118-127. https://doi.org/10.1177/1479164119827611.
Govers E, Slof E, Verkoelen H, Ten Hoor-Aukema NM. Int J Endocrinol Metab Disord 2015;1(4). https://doi.org/10.16966/2380-548X.115.
Church TJ, Haines ST. Clin Diabetes 2016;34(2): 97-104. https://doi.org/10.2337/diaclin.34.2.97.